Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Short term Debt (2016 - 2025)

Abeona Therapeutics (ABEO) has 11 years of Short term Debt data on record, last reported at $8.9 million in Q3 2025.

  • For Q3 2025, Short term Debt rose 100.02% year-over-year to $8.9 million; the TTM value through Sep 2025 reached $8.9 million, up 100.02%, while the annual FY2024 figure was $5.9 million, N/A changed from the prior year.
  • Short term Debt reached $8.9 million in Q3 2025 per ABEO's latest filing, up from $5.6 million in the prior quarter.
  • Across five years, Short term Debt topped out at $34.4 million in Q2 2021 and bottomed at $2.2 million in Q2 2024.
  • Average Short term Debt over 4 years is $10.9 million, with a median of $5.6 million recorded in 2025.
  • Peak YoY movement for Short term Debt: soared 1037.66% in 2021, then plummeted 86.01% in 2022.
  • A 4-year view of Short term Debt shows it stood at $4.6 million in 2021, then increased by 7.0% to $4.9 million in 2022, then grew by 20.42% to $5.9 million in 2024, then surged by 50.0% to $8.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $8.9 million in Q3 2025, $5.6 million in Q2 2025, and $8.1 million in Q1 2025.